This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, L. Articles by Christiani, D. C. Search for Related Content PubMed PubMed Citation Articles by Su, L. Articles by Christiani, D. C.

Matrix Metalloproteinase-1 Promoter Polymorphism and Lung Cancer Risk

¹ Occupational Health Program, Departments of Environmental Health and ² Biostatistics, Harvard School of Public Health, Boston, Massachusetts; ³ Thoracic Surgery Unit, Departments of Surgery and ⁴ Hematology-Oncology, and ⁵ Pulmonary and Critical Care Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

Requests for reprints: David C. Christiani, Harvard School of Public Health, 665 Huntington Avenue, Boston, MA 02115. Tel: 617-432-3323; Fax: 617-432-6981. E-mail: dchristi{at}hsph.harvard.edu

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Extracellular matrix-degrading matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that degrades the interstitial types I, II, and III collagens, and overexpression of MMP-1 is associated with cancer development and cellular invasion. The 2G allele of the MMP-1 –1607 1G/2G polymorphism is associated with enhanced transcriptional activity. We investigated the association between the MMP-1 1G/2G polymorphism and lung cancer risk in 1,752 Caucasian lung cancer patients and 1,363 healthy controls. There were no overall associations between the MMP-1 genotypes and risk of lung cancer, with the adjusted odds ratios of 1.15 [95% confidence interval (CI), 0.94-1.40] for the 1G/2G genotype and 1.14 (95% CI, 0.90-1.45) for the 2G/2G genotype, when versus the 1G/1G genotype. Stratified analyses suggested higher lung cancer risk for the 2G allele in never-smokers and males, with the adjusted odds ratios of 1.67 (95% CI, 1.02-2.76; 1G/2G) and 1.50 (95% CI, 0.86-2.62; 2G/2G) in never-smokers; and 1.30 (95% CI, 1.00-1.75; 1G/2G) and 1.23 (95% CI, 0.88-1.73; 2G/2G) in males, respectively. In conclusion, genotypes containing the 2G allele of the MMP-1 polymorphism are associated with higher risk of lung cancer in never-smokers and in males.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The matrix metalloproteases (MMP) are a family of secreted zinc metalloproteases that degrade the extracellular matrix collagens. MMP-1 (collagenase) may degrade the interstitial types I, II, and III collagens (1) and contribute to tumor initiation and development by altering the cellular microenvironment that facilitates tumor formation (2-4). There is a single nucleotide polymorphism at –1,607 bp in the MMP-1 promoter, with the 2G allele associated with higher expression levels (5, 6). Cells expressing the 2G allele may provide a mechanism for more aggressive matrix degradation, thereby facilitating cancer progression. The MMP-1 2G/2G genotype has been associated with significantly higher risk of lung cancer in one previous study, specifically for males, current smokers, and heavy smokers (3). We hypothesized that the 2G allele of the MMP-1 1G/2G polymorphism is associated with higher risk of lung cancer in our large case-control population.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Study Population and Genotyping
The study was approved by the Human Subjects Committees of Massachusetts General Hospital and the Harvard School of Public Health, Boston, MA. Details of this case-control population have been described previously (7, 8). In brief, all eligible histologically confirmed lung cancers were recruited at Massachusetts General Hospital between December 1992 and April 2003. Unmatched controls were recruited among healthy friends and non–blood-related family members (usually spouses) of cancer patients or patients with a cardiothoracic condition undergoing surgery. Over 85% of eligible cases and >90% of controls participated in this study and provided blood samples. Interviewer-administered questionnaires collected information on demographic and detailed smoking histories from each subject. The MMP1 –1607 1G/2G polymorphism was genotyped by the 5' nuclease assay (TaqMan) using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA).

Statistical Analysis
Although individuals of all races were recruited for this study, we restricted our analyses to Caucasians (97%) in order to minimize confounding due to allele frequency variation by ethnicity. Logistic regression models were fit to examine the relationship between the log odds of lung cancer and each covariate, after adjusting for possible confounding factors such as age, gender, smoking status, pack-years of smoking, and years since smoking cessation (if ex-smoker, defined as those who quit smoking more than a year before recruitment). As suggested before, square root transformed pack-years of smoking were used in the analyses instead of the original untransformed variable (7). In addition to the overall association analysis, we did a stratified analysis by gender, age, smoking status, histology, and clinical stages, to further explore the association between MMP-1 polymorphism and the risk of lung cancer in each stratum. Case-only analyses were done to investigate the effect of MMP-1 polymorphism on different histologic subtypes or clinical stages among lung cancer patients. Statistical analyses were undertaken using SAS statistical packages (SAS Institute, Cary, NC).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Population Characteristics
A total of 3,413 (99.6%) of 3,426 enrolled subjects were genotyped successfully for the MMP-1 polymorphism. Complete information on race, age, gender, and detailed smoking variables was available for 3,219 subjects (94%). Of these, there were 1,752 Caucasian lung cancer cases and 1,363 Caucasian controls. The distributions of demographic characteristics for cases and controls are summarized in Table 1. Compared to the controls, cases were older, had a higher proportion of males, were more likely to be current smokers or heavy smokers, and had a shorter time since smoking cessation (if an ex-smoker) and larger pack-years of cigarette smoking.

No statistically significant association was found between MMP-1 polymorphism and lung cancer risk in younger or older subjects (Table 2). Statistically significant higher lung cancer risk (only for the 1G/2G genotype) was found in males but not in females, with the adjusted ORs for 1G/2G and 2G/2G genotypes (when using the 1G/1G genotype as reference) of 1.30 (95% CI, 1.00-1.75) and 1.23 (95% CI, 0.88-1.73) in males, and 0.99 (95% CI, 0.74-1.32) and 1.05 (95% CI, 0.75-1.46) in females, respectively. For different smoking categories, statistically higher lung cancer risk (only for the 1G/2G genotype) was found in never-smokers, with the adjusted ORs for 1G/2G and 2G/2G genotypes (when versus the 1G/1G genotype) of 1.67 (95% CI, 1.02-2.76) and 1.50 (95% CI, 0.86-2.62), respectively. No associations were found in ex-smokers or current smokers, or in different pack-years of smoking (Table 2).

Association Between MMP-1 Genotypes and Lung Cancer Risk in Different Histologic and Disease Stages
For different histologic subtypes of lung cancer, higher lung cancer risk of MMP-1 polymorphism was found for patients with adenocarcinoma than for patients with squamous cell carcinoma (when each was compared with all controls), with the adjusted ORs for 1G/2G and 2G/2G genotypes (when versus the 1G/1G genotype) of 1.20 (95% CI, 0.95-1.52) and 1.21 (95% CI, 0.92-1.59), respectively, for patients with adenocarcinoma; and 0.93 (95% CI, 0.66-1.31), and 0.72 (95% CI, 0.47-1.11), respectively, for squamous cell carcinoma patients (Table 3). In case-only analysis, the adjusted ORs of adenocarcinoma versus squamous cell carcinoma for 1G/2G and 2G/2G genotypes were 1.12 (95% CI, 0.83-1.51) and 1.51 (95% CI, 1.04-2.20), respectively. By gender, the histologic difference of MMP-1 polymorphism was found in males only, and not in females, with the case-only adjusted ORs (adenocarcinoma versus squamous cell carcinoma) for the 1G/2G and 2G/2G genotypes were 1.25 (95% CI, 0.85-1.85) and 1.88 (95% CI, 1.16-3.07) in males; and 0.90 (95% CI, 0.55-1.48) and 1.05 (95% CI, 0.58-1.91) in females.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Carcinogenesis is a multicellular and multistage process in which the destruction of the microenvironment is required for the conversion of normal tissue to tumor. MMPs may alter cell cycle checkpoint controls, conceivably promote genomic instability by affecting cell adhesion (9), and alter the microenvironment that can influence tumor formation and play an important role in several steps of cancer development (3). MMP-1 is the most highly expressed interstitial collagenase degrading fibrillar collagens. Overexpression of MMP-1 has been associated with higher risks of lung cancer (10, 11).

In this study, the MMP-1 2G allele was associated with higher lung cancer risk in never-smokers, but not in ex- or current smokers, nor in any of the smoking subgroups. One possible explanation is that although cigarette smoking may increase MMP-1 mRNA levels and MMP-1 activity (12, 13), smoking may also increase the mRNA levels of tissue inhibitors of metalloprotease (14, 15). Therefore, the effect of MMP-1 polymorphism in smokers may depend on the balances between MMPs and tissue inhibitors of metalloprotease. The results are inconsistent with a previous study where the 2G/2G genotype was found to be associated with higher lung cancer risk in current smokers and heavy smokers, and not in never-smokers (3). However, the genotype distribution of this polymorphism was out of Hardy-Weinberg equilibrium in the control population for the previous study, and the 1G/2G genotype was combined with the 1G/1G genotype in all analyses. Further studies are needed to investigate the effect of cigarette smoking on the expression levels of different genotypes of MMP-1.

Consistent with the previous study (3), we found that lung cancer risk conferred by the 2G allele was higher in males than females. Similar gender differences in risk for the MMP-1 polymorphism were also found for renal cell and gastric cancer patients (16, 17). Sex hormones including progesterone, estradiol, and ovarian steroids levels may decrease the MMP-1 expression levels and increase the tissue inhibitor levels of MMP-1 proteins (18-20). Therefore, females may have lower MMP-1 levels than males, and estrogen levels may be more important in the influence on the expression levels of MMP-1 than the polymorphism (16).

For different histologic subtypes of patients, we observed a higher risk of the 2G allele for patients with adenocarcinoma when compared with patients with squamous cell carcinoma, specifically for males. This finding is echoed in a study that reported adenocarcinoma overexpressed MMP-1 more frequently than squamous cell carcinoma in non–small cell lung cancer tissues (21). The mechanism for this histologic difference is still under investigation, but there are two distinct theories. The MMP-1 –1607 1G/2G polymorphism is adjacent to an activating protein-1 site at –1,602 bp, which may cooperate with the 2G allele (Ets site) to induce higher levels of transcription (5), and the activator protein-1 site is inhibitory in the context of the 1G allele, but activating the 2G allele (6). If this activator protein-1 site is mutated, it could lead to a substantial increase in expression of the 1G allele where the difference in transcription between 1G and 2G alleles is abolished and the MMP-1 expression is similar between the two alleles (6). It is possible that activator protein-1 mutant frequencies are different between different histologic subtypes of lung cancer, which may induce the differential association between MMP-1 polymorphism and lung cancer risk by histologic subtypes. An alternative explanation is that squamous cell carcinoma tumor tissues have been found to have higher rates of p53 mutations than adenocarcinoma tissues (22). MMP-1 is a target of the p53 protein, and wild-type p53 can exert a strong inhibitory effect on the human MMP-1 promoter by disrupting communications between the transactivator –72AP-1 and the basal transcriptional complex, whereas p53 mutants lose such repressive activity (23, 24). The down-regulation of the human MMP1 promoter by p53 was abolished after the proximal –72AP-1 site was deleted or mutated (24). Therefore, mutated p53 may lose the ability of regulating MMP-1 transcription.

There are several limitations to this study. Firstly, this is a hospital-based case-control study, where a subset of the controls included healthy spouses and friends of patients with lung cancer. Secondly, we only evaluated the MMP-1 –1607 1G/2G polymorphism that has been suggested to be associated with MMP-1 expression levels, which may result in some misclassification in MMP-1 action. It is possible that other polymorphisms might also be associated with MMP-1 expression levels, which may be one reason why we observed a stronger association for the 1G/2G genotype than the 2G/2G genotype in most of the comparisons. Thirdly, although we adjusted for various smoking variables in all of the analyses, secondhand smoke exposure, alcohol consumption, diet, and environmental and occupational exposure data were not adjusted in our logistic regression models because of missing or incomplete information. Lastly, we did multiple comparisons through subgroup analyses. It is possible that the borderline significant results could be due to multiple comparisons. Given our sample size, we have tried as much as possible to avoid the bias by careful a priori specification of our primary hypotheses.

In conclusion, the 2G allele of the MMP-1 –1607 1G/2G polymorphism is associated with higher lung cancer risk in never-smokers and males, where the risk is mostly attributable to patients with adenocarcinoma.

	Acknowledgments

 
We thank the following staff members of the Lung Cancer Susceptibility Group: Barbara Bean, Jessica Shin, Andrea Solomon, Andrea Shafer, Thomas Van Geel, Lucy Ann Principe, Salvatore Mucci, Richard Rivera-Massa, David P. Miller, Steven Su, and the generous support of Dr. Panos Fidias and the physicians and surgeons of the Massachusetts General Hospital Cancer Center.

	Footnotes

 
Grant support: NIH grants CA74386, CA90578, ES/CA 06409, Flight Attendants Medical Research Institute Young Clinical Scientist Award, and a Doris Duke Clinician Scientist Award.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: L. Su and W. Zhou contributed equally to this work.

Received 6/29/04; revised 9/ 9/04; accepted 10/27/04.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Vincenti MP, White LA, Schroen DJ, Benbow U, Brinckerhoff CE. Regulating expression of the gene for matrix metalloproteinase-1 (collagenase): mechanisms that control enzyme activity, transcription, and mRNA stability. Crit Rev Eukaryot Gene Expr 1996;6:391–411.[Medline]
2. Galateau-Salle FB, Luna RE, Horiba K, et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in bronchial squamous preinvasive lesions. Hum Pathol 2000;31:296–305.[CrossRef][Medline]
3. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 2001;61:7825–9.[Abstract/Free Full Text]
4. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74.[Medline]
5. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998;58:5321–5.[Abstract/Free Full Text]
6. Tower GB, Coon CI, Brinckerhoff CE. The 2G single nucleotide polymorphism (SNP) in the MMP-1 promoter contributes to high levels of MMP-1 transcription in MCF-7/ADR breast cancer cells. Breast Cancer Res Treat 2003;82:75–82.[CrossRef][Medline]
7. Xu LL, Wain JC, Miller DP, et al. The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior. Cancer Epidemiol Biomarkers Prev 2001;10:303–9.[Abstract/Free Full Text]
8. Miller DP, Liu G, DeVivo I, et al. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res 2002;62:2819–23.[Abstract/Free Full Text]
9. Tlsty TD. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol 1998;10:647–53.[CrossRef][Medline]
10. Pritchard SC, Nicolson MC, Lloret C, et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001;8:421–4.[Medline]
11. Schutz A, Schneidenbach D, Aust G, Tannapfel A, Steinert M, Wittekind C. Differential expression and activity status of MMP-1, MMP-2 and MMP-9 in tumor and stromal cells of squamous cell carcinomas of the lung. Tumour Biol 2002;23:179–84.[CrossRef][Medline]
12. Lahmann C, Bergemann J, Harrison G, Young AR. Matrix metalloproteinase-1 and skin ageing in smokers. Lancet 2001;357:935–6.[CrossRef][Medline]
13. Selman M, Cisneros-Lira J, Gaxiola M, et al. Matrix metalloproteinases inhibition attenuates tobacco smoke-induced emphysema in guinea pigs. Chest 2003;123:1633–41.[Abstract/Free Full Text]
14. Morimoto Y, Tsuda T, Nakamura H, et al. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and extracellular matrix mRNA following exposure to mineral fibers and cigarette smoke in vivo. Environ Health Perspect 1997;105 Suppl 5:1247–51.
15. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Chung KF. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000;162:1355–60.[Abstract/Free Full Text]
16. Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 2003;106:372–4.[CrossRef][Medline]
17. Matsumura S, Oue N, Kitadai Y, et al. A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol 2004.
18. Nakopoulou L, Giannopoulou I, Gakiopoulou H, Liapis H, Tzonou A, Davaris PS. Matrix metalloproteinase-1 and -3 in breast cancer: correlation with progesterone receptors and other clinicopathologic features. Hum Pathol 1999;30:436–42.[CrossRef][Medline]
19. Singer CF, Marbaix E, Kokorine I, et al. The matrix metalloproteinase-1 (MMP-1) expression in the human endometrium is inversely regulated by interleukin-1 and sex steroids. Ceska Gynekol 2000;65:211–5.[Medline]
20. Chen B, Wen Y, Wang H, Polan ML. Differences in estrogen modulation of tissue inhibitor of matrix metalloproteinase-1 and matrix metalloproteinase-1 expression in cultured fibroblasts from continent and incontinent women. Am J Obstet Gynecol 2003;189:59–65.[CrossRef][Medline]
21. Thomas P, Khokha R, Shepherd FA, Feld R, Tsao MS. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000;190:150–6.[CrossRef][Medline]
22. Gao WM, Mady HH, Yu GY, et al. Comparison of p53 mutations between adenocarcinoma and squamous cell carcinoma of the lung: unique spectra involving G to A transitions and G to T transversions in both histologic types. Lung Cancer 2003;40:141–50.[CrossRef][Medline]
23. Sun Y, Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J Biol Chem 1999;274:11535–40.[Abstract/Free Full Text]
24. Sun Y, Zeng XR, Wenger L, Firestein GS, Cheung HS. P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 2004;92:258–69.[CrossRef][Medline]

This article has been cited by other articles:

				W. Sauter, A. Rosenberger, L. Beckmann, S. Kropp, K. Mittelstrass, M. Timofeeva, G. Wolke, A. Steinwachs, D. Scheiner, E. Meese, et al. Matrix Metalloproteinase 1 (MMP1) Is Associated with Early-Onset Lung Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1127 - 1135. [Abstract] [Full Text] [PDF]

				J. Decock, J.-R. Long, R. C. Laxton, X.-O. Shu, C. Hodgkinson, W. Hendrickx, E. G. Pearce, Y.-T. Gao, A. C. Pereira, R. Paridaens, et al. Association of Matrix Metalloproteinase-8 Gene Variation with Breast Cancer Prognosis Cancer Res., November 1, 2007; 67(21): 10214 - 10221. [Abstract] [Full Text] [PDF]

				K. S. Mix, M. G. Attur, H. Al-Mussawir, S. B. Abramson, C. E. Brinckerhoff, and E. P. Murphy Transcriptional Repression of Matrix Metalloproteinase Gene Expression by the Orphan Nuclear Receptor NURR1 in Cartilage J. Biol. Chem., March 30, 2007; 282(13): 9492 - 9504. [Abstract] [Full Text] [PDF]

				A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote The molecular epidemiology of lung cancer Carcinogenesis, March 1, 2007; 28(3): 507 - 518. [Abstract] [Full Text] [PDF]

				E. G. Pearce, R. C. Laxton, A. C. Pereira, and S. Ye Haplotype Effects on Matrix Metalloproteinase-1 Gene Promoter Activity in Cancer Cells Mol. Cancer Res., March 1, 2007; 5(3): 221 - 227. [Abstract] [Full Text] [PDF]

				T. Sun, Y. Gao, W. Tan, S. Ma, X. Zhang, Y. Wang, Q. Zhang, Y. Guo, D. Zhao, C. Zeng, et al. Haplotypes in Matrix Metalloproteinase Gene Cluster on Chromosome 11q22 Contribute to the Risk of Lung Cancer Development and Progression Clin. Cancer Res., December 1, 2006; 12(23): 7009 - 7017. [Abstract] [Full Text] [PDF]

				K.-A. Yoon, B. Hwangbo, I.-J. Kim, S. Park, H. S. Kim, H. J. Kee, J. E. Lee, Y. K. Jang, J.-G. Park, and J. S. Lee Novel polymorphisms in the SUV39H2 histone methyltransferase and the risk of lung cancer Carcinogenesis, November 1, 2006; 27(11): 2217 - 2222. [Abstract] [Full Text] [PDF]

				R. S. Heist, A. L. Marshall, G. Liu, W. Zhou, L. Su, D. Neuberg, T. J. Lynch, J. Wain, and D. C. Christiani Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. Clin. Cancer Res., September 15, 2006; 12(18): 5448 - 5453. [Abstract] [Full Text] [PDF]

				L. Su, W. Zhou, K. Asomaning, X. Lin, J. C. Wain, T. J. Lynch, G. Liu, and D. C. Christiani Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer Carcinogenesis, May 1, 2006; 27(5): 1024 - 1029. [Abstract] [Full Text] [PDF]

				Z. Hu, X. Huo, D. Lu, J. Qian, J. Zhou, Y. Chen, L. Xu, H. Ma, J. Zhu, Q. Wei, et al. Functional Polymorphisms of Matrix Metalloproteinase-9 Are Associated with Risk of Occurrence and Metastasis of Lung Cancer Clin. Cancer Res., August 1, 2005; 11(15): 5433 - 5439. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Su, L. Articles by Christiani, D. C. Search for Related Content PubMed PubMed Citation Articles by Su, L. Articles by Christiani, D. C.